Lung Cancer
Издатель: Elsevier · ISSN 0169-5002 · 69 статей
- Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review
- Lung cytology in the diagnostic workflow: A real-world study of its clinical impact
- TLS-related immune organization and regional IRF4 expression in pretreatment biopsies of advanced lung adenocarcinoma
- Lung cancer after allogeneic hematopoietic stem cell transplantation
- Patient-reported outcomes from the phase 3 IMforte study of first-line maintenance treatment with lurbinectedin + atezolizumab versus atezolizumab in patients with extensive-stage small cell lung cancer
- Beyond disease-free survival in adjuvant ALK-targeted therapy: lessons from ELEVATE and ALINA
- Corrigendum to “The safety of extended dosing pembrolizumab when compared to traditional dosing: a review and meta-analysis of retrospective studies” [Lung Cancer 204 (2025) 108585]
- A Wide pCR Divide: Neoadjuvant immunotherapy versus targeted therapy in resectable NSCLC
- Bridging the molecular and immune landscapes of pleural mesothelioma: Implications for immune checkpoint inhibitor response
- Two decades of progress in lung cancer outcomes in Australia: Population-based trends by histological subtype and stage at diagnosis
- Decoding immune signatures driving brain metastases in stage III non-small cell lung cancer
- Navitoclax overcomes epithelial–mesenchymal transition-associated resistance in ALK-positive non-small cell lung cancer with rapid disease progression during alectinib treatment
- Platinum rechallenge as a reasonable treatment option for selected SCLC patients
- HER2 status in Diffuse pleural mesothelioma
- Multi-omics liquid biopsy for leptomeningeal metastases in lung cancer: from molecular mechanisms to precision diagnosis and treatment
- Targeting MYC in small cell lung cancer: Bridging molecular subtypes and therapeutic vulnerability
- Lung cancer associated with cystic airspaces (LCCA): A comprehensive literature review undertaken as part of the British thoracic oncology group (BTOG) work programme
- Adverse events in placebo arms of phase III lung cancer trials: a systematic review and meta-analysis
- Emerging molecular probes for lung cancer: Targets, translational evidence, and theranostic potential
- Efficacy and safety of adjuvant ensartinib in stage I ALK-positive NSCLC patients: a retrospective, multicenter study
- Real-world effectiveness and safety of lurbinectedin in previously treated small cell lung cancer: results from Jazz EMERGE 402
- Exosomal miR-3662 originating from M2-polarized macrophages facilitates cisplatin resistance of lung adenocarcinoma cells through inhibiting the IRF8/RASSF5 cascade and boosting autophagy
- From whole-exome sequencing to functional insight: Characterization of rare germline variants in lung cancer
- Integrated histopathological, immunohistochemical, and molecular profiling reveals hidden heterogeneity within histologic subtypes of thymoma
- Multicenter case series of pulmonary sclerosing pneumocytoma coinciding with typical carcinoid: Shared AKT1 p.E17K mutation in mixed-growth lesions
- Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum–etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational study (G-GUARD; TORG-TG2504)
- Association of the IASLC histologic grading system with aggressive pathologic features in invasive non-mucinous lung adenocarcinoma
- First Korean experience with shape-sensing robotic-assisted bronchoscopy integrated with mobile cone-beam CT: Results from the prospective ULSAN-ION study
- Radiologic phenotype and the size dependence of adverse histologic features and recurrence in resected lung adenocarcinoma
- Environmental asbestos exposure and lung cancer burden: Considerations of the dose–response